PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27015562-3	2016	Multiplex assays performed on tumor material that survived and re-grew after [pemetrexed + sorafenib] exposure showed increased phosphorylation of ERBB1 and of NFkappaB and IkappaB; with reduced IkappaB and elevated G-CSF and KC protein levels.	Sorafenib	91-100	colony stimulating factor 3	Homo sapiens	216-221	
20845054-0	2011	Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor.	Sorafenib	25-34	colony stimulating factor 3	Homo sapiens	78-115	
20845054-1	2011	We present the first case report of the use of sorafenib and S-1 for the treatment of renal cell carcinoma (RCC) producing granulocyte colony-stimulating factor (G-CSF).	Sorafenib	47-56	colony stimulating factor 3	Homo sapiens	123-160	
20845054-1	2011	We present the first case report of the use of sorafenib and S-1 for the treatment of renal cell carcinoma (RCC) producing granulocyte colony-stimulating factor (G-CSF).	Sorafenib	47-56	colony stimulating factor 3	Homo sapiens	162-167	
20845054-6	2011	New combination therapy with sorafenib and S-1 exerted a therapeutic effect and apparently decreased serum and urinary G-CSF levels, although the patient died of gastrointestinal perforation.	Sorafenib	29-38	colony stimulating factor 3	Homo sapiens	119-124	
20845054-7	2011	The use of combined sorafenib and S-1 may be worthy of consideration in the treatment of RCC producing G-CSF.	Sorafenib	20-29	colony stimulating factor 3	Homo sapiens	103-108